n South African Gastroenterology Review - Revellex® (infliximab) now indicated for ulcerative colitis and paediatric crohn's disease : product news
|Article Title||Revellex® (infliximab) now indicated for ulcerative colitis and paediatric crohn's disease : product news|
|© Publisher:||In House Publications|
|Journal||South African Gastroenterology Review|
|Publication Date||Aug 2009|
|Pages||28 - 29|
Revellex® (infliximab) is a monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α), which has been shown to play a role in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, paediatric Crohn's disease, psoriatic arthritis, and plaque psoriasis. Revellex is the global market leader among anti-TNF-α therapies and was the first agent approved for the treatment of both ulcerative colitis and Crohn's disease.
Article metrics loading...